ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce that in February the Company recorded its highest monthly revenue and profit in its 23-year history. ITL BioMedical and ITL Healthcare both achieved record months.
ITL Healthcare saw an increase in sales of its IV Starter Kit and ITL BioMedical began initial supply of products under the global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with bioMérieux (Euronext:BIM), a multinational biotechnology company, as announced in October 2016.
In February ITL announced profit after tax of $2.1m for the 6 months to 31st December, up 104% from the corresponding 2015 period and revenues of $17.5m, up 11%. The Board stated it expects “a strong result for the full financial year even allowing for some seasonality in the 2nd half year.”
Bill Mobbs, ITL Executive Chairman commented; “this is the culmination of a lot of hard work across ITL Health Group. Whilst February sales included some initial stocking up, we are confident that this is the first step in the anticipated growth of SSK product sales in the future.”